 SOUTH SAN FRANCISCO, Calif., May 23, 2021 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. Nasdaq: NGM will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET 5:30 a.m. PT to discuss topline results from the 24-week Phase 2b ALPINE 23 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows: 